All In Biotech

Drug Trial Radar · NCT04570332

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

Phase 2 Single Arm Clinical Study to Evaluate the Efficacy and Safety of Intratumoral Administration of BO-112 in Combination With Pembrolizumab in Subjects That Have Progressed on Anti-PD-1-based Therapy for Stage III or IV Melanoma

Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

42

Actual

Start

Dec 30, 2020

Primary completion

Oct 3, 2023

Study completion Nov 4, 2024

Sponsor

Lead sponsor
Highlight TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Sep 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab. The study will enroll patients with advanced and/or metastatic melanoma that have progressed on anti-PD-1-containing treatment.

Conditions

  • Melanoma

Interventions

  • BO-112 plus pembrolizumabDrug

    Patients will be treated with the combination of BO-112 and pembrolizumab. Order of administration should be pembrolizumab then IT BO-112. BO-112 will be administered IT at a total dose of 1-2 mg at each administration to 1-8 tumor lesions using tuberculin (TB) syringes (or equivalent) with 20- to 25-gauge needles

  • Tissue BiopsiesProcedure

    Pre and post (if feasible) treatment tumor tissue biopsies will be used for correlative research.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response RateTime frame: From the first dose of study treatment to the date of CR or PR assessed up to 2 years

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux, France

  • Centre Hospitalier Universitaire de Grenoble

    Grenoble, France

  • Hopital Lyon Sud

    Lyon, France

  • Centre Hospitalier Universitaire de Nantes

    Nantes, France

  • Centre Hospitalier Universitaire de Nice

    Nice, France

  • Hôpital Ambroise-Paré

    Paris, France

  • Institut Gustave Roussy

    Paris, France

  • H. Universitari Quirón Dexeus

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Clara Campal - HM Sanchinarro

    Madrid, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • MD Anderson Cancer Center

    Madrid, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia, Spain

  • Clínica Universidad de Navarra

    Pamplona, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • H. General Universitario de Valencia

    Valencia, Spain

  • H. Universitari Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Tenerife, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.